

CLAIMS

1. An agent for the prophylaxis or treatment of drug-induced neuropathy, which comprises cytidine 5'-diphosphocholine or a pharmaceutically acceptable salt thereof as an active
5 ingredient.
2. The agent of claim 1, wherein the drug-induced neuropathy is peripheral neuropathy.
- 10 3. The agent of claim 1, which is in a dosage form for oral administration.
4. The agent of claim 1, wherein the drug-induced neuropathy is induced by a pharmaceutical product selected from the group
15 consisting of antidepressant, antiepileptic agent, antituberculosis agent, antibiotics, anti-malignant tumor agent, a therapeutic agent for AIDS, antirheumatic agent, antiarrhythmic agent, dermatological agent used for Reye syndrome, antialcoholic agent against excessive alcohol
20 drinking, antihypertensive agent, radiation sensitizer, vitamin and immunosuppressant.
5. The agent of claim 1, wherein the drug-induced neuropathy is induced by poisonoum substance or ethanol.
25
6. A method for the prophylaxis or treatment of drug-induced neuropathy, which comprises administering an effective amount of cytidine 5'-diphosphocholine or a pharmaceutically acceptable salt thereof to a patient.
30
7. The method of claim 6, wherein the drug-induced neuropathy is peripheral neuropathy.
8. The method of claim 6, wherein the administration comprises
35 oral administration.

9. The method of claim 6, wherein the drug-induced neuropathy is induced by a pharmaceutical product selected from the group consisting of antidepressant, antiepileptic agent,
5 antituberculosis agent, antibiotics, anti-malignant tumor agent, a therapeutic agent for AIDS, antirheumatic agent, antiarrhythmic agent, dermatological agent used for Reye syndrome, antialcoholic agent against excessive alcohol drinking, antihypertensive agent, radiation sensitizer, vitamin
10 and immunosuppressant.
10. The method of claim 6, wherein the drug-induced neuropathy is neuropathy induced by poisonoum substance or ethanol.
- 15 11. Use of cytidine 5'-diphosphocholine or a pharmaceutically acceptable salt thereof for the production of an agent for the prophylaxis or treatment of drug-induced neuropathy.
12. Use of claim 11, wherein the drug-induced neuropathy is
20 peripheral neuropathy.
13. Use of claim 11, wherein the agent is in a dosage form for oral administration.
- 25 14. Use of claim 11, wherein the drug-induced neuropathy is neuropathy induced by a pharmaceutical product selected from the group consisting of antidepressant, antiepileptic agent, antituberculosis agent, antibiotics, anti-malignant tumor agent, a therapeutic agent for AIDS, antirheumatic agent,
30 antiarrhythmic agent, dermatological agent used for Reye syndrome, antialcoholic agent against excessive alcohol drinking, antihypertensive agent, radiation sensitizer, vitamin and immunosuppressant.
- 35 15. Use of claim 11, wherein the drug-induced neuropathy is

neuropathy induced by a poisonoum substance or ethanol.

16. A pharmaceutical composition for the prophylaxis or treatment of drug-induced neuropathy, which comprises an
5 effective amount of cytidine 5'-diphosphocholine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 16, wherein the
10 drug-induced neuropathy is peripheral neuropathy.

18. The pharmaceutical composition of claim 16, which is in a dosage form for oral administration.

15 19. The pharmaceutical composition of claim 16, wherein the drug-induced neuropathy is neuropathy induced by a pharmaceutical product selected from the group consisting of antidepressant, antiepileptic agent, antituberculosis agent, antibiotics, anti-malignant tumor agent, a therapeutic agent
20 for AIDS, antirheumatic agent, antiarrhythmic agent, dermatological agent used for Reye syndrome, antialcoholic agent against excessive alcohol drinking, antihypertensive agent, radiation sensitizer, vitamin and immunosuppressant.

25 20. The pharmaceutical composition of claim 16, wherein the drug-induced neuropathy is neuropathy induced by a poisonoum substance or ethanol.

21. A commercial package comprising the pharmaceutical
30 composition of claim 16 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the prophylaxis or treatment of drug-induced neuropathy.